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Serum metabolite proﬁle associates with the development
of metabolic co-morbidities in ﬁrst-episode psychosis
T Suvitaival1, O Mantere2,3,4, T Kieseppä2,5, I Mattila1, P Pöhö6, T Hyötyläinen1,7, J Suvisaari2 and M Orešič1,8
Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities
are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier
metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the
general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite proﬁles
predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to
investigate serum metabolite proﬁles in a prospective study setting in 36 ﬁrst-episode psychosis patients during the ﬁrst year of the
antipsychotic treatment and 19 controls. While corroborating several earlier ﬁndings when comparing cases and controls and the
effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with
increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be
associated with increased liver fat. Our study suggests that metabolite proﬁles may be used to identify the psychotic patients
most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the
antipsychotic-induced weight gain.
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INTRODUCTION
Patients with ﬁrst-episode psychosis (FEP) have high risk of weight
gain, glucose dysregulation and dyslipidemias during the early
stages of illness.1,2 Although some of these cardiometabolic risk
factors may be present already before the initiation of treatment,3
cardiovascular risk increases after exposure to antipsychotic
drugs.4 Weight gain is most rapid during the ﬁrst months of
treatment, after which weight gradually stabilizes.5 Antipsychotic
drugs differ in their propensity to cause weight gain and other
metabolic side effects.4,6 Unfortunately, clozapine and olanzapine,
which are among the most efﬁcacious antipsychotics, are also the
most likely to cause cardiometabolic side effects.4,6–8 However,
there is signiﬁcant individual variation in the propensity to
antipsychotic-induced weight gain and other metabolic altera-
tions, some of which may be genetically mediated.9–11 To
optimize the effectiveness and tolerability of treatment, biomar-
kers for early identiﬁcation of psychotic patients at high risk of
weight gain and the development of associated cardiometabolic
co-morbidities would be highly useful in clinical practice.
Metabolomics, and lipidomics as one of its branches, are
promising new tools for the identiﬁcation of biomarkers for both
etiopathology of psychotic disorders and antipsychotic side
effects.12–17 Metabolomics has also had an important role to
unravel putative biomarkers and underlying pathways in several
other diseases of the central nervous system,18 including
major depressive disorder19,20 as well as Alzheimer’s21-24 and
Parkinsons25–27 diseases.
In the general population, speciﬁc metabolites are also
predictive of development of insulin resistance,28 non-alcoholic
fatty liver disease29 and type 2 diabetes.30,31 All these conditions
are known co-morbidities of psychotic disorders. However,
previous studies have not investigated metabolomic proﬁles
which might be valuable to identify the risk of early weight gain
or other metabolic abnormalities in psychotic patients. Here we set
out to investigate aberrations in blood metabolite levels in FEP
patients at early stages of the antipsychotic treatment, and
followed-up the development of the patients in order to associate
the observed aberrations with clinical outcomes.
MATERIALS AND METHODS
Ethics statement
The study protocol was approved by the Ethics Committee of the Hospital
District of Helsinki and Uusimaa (257/12/03/03/2009) and by the
institutional review boards of the National Institute for Health and Welfare,
Helsinki, Finland, and the University of Helsinki, and all participants gave a
written informed consent. Patient’s capacity to give informed consent was
assessed by the treating psychiatrist.
Clinical study protocol
The study sample and protocol have been previously described in detail in
a previous publication.32 Patients (aged 18 to 40 years) with FEP were
recruited from the catchment area of the Helsinki University Hospital.
Psychosis was deﬁned as receiving a score of at least 4 in the items
assessing delusions or hallucinations in the Brief Psychiatric Rating Scale-
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Extended (BPRS-E).33 Patients were assessed clinically three times. The
baseline assessment was done as soon as the patient had entered
treatment and was able to give informed consent, and the follow-ups were
done at 2 and 12 months. Each assessment included BPRS-E. In addition,
diagnostic assessment was done at 2 months and 1-year follow-up based
on the Research Version of the Structured Clinical Interview for DSM-IV and
all information from medical records, and DSM-IV diagnosis was done by a
senior psychiatrist (JS) together with the interviewer. Data were also
gathered on sociodemographic factors, medication, substance use,
physical activity, diet and smoking, and the interviewer measured weight,
height, blood pressure and waist circumference. Global Assessment of
Functioning (GAF) was used as an overall measure of psychological, social
and occupational functioning.32
Controls were recruited from the Population Register Centre. Their
baseline assessment was identical to the patients’ protocol.
Blood samples. A fasting blood sample (serum and plasma) was collected
on the morning following the interview at 8 to 10 am at baseline,
2 months, and 1 year, for patients and at baseline for controls. Samples
were immediately aliquoted and stored at − 80 oC.
Serum total cholesterol, high-density lipoprotein cholesterol, triglycerides,
apolipoprotein A-I (ApoA-I) and B (ApoB) and plasma glucose were
measured with enzymatic assays by the Abbott Architect ci8200 analyzer
(Abbott Laboratories, Abbott Park, IL, USA). Apolipoprotein A-I (ApoA-I) and
B were determined with immunoturbimetric assays (Abbott) and high
sensitivity C-reactive protein (hs-CRP) with latex turbidometric immuno-
assay (Sentinel, Milan, Italy). Insulin and C-peptide were measured with
chemiluminescent microparticle immunoassays (Abbott). Low-density
lipoprotein cholesterol was calculated by the Friedewald formula. The
mean inter-assay coefﬁcient of variations (CVs) for cholesterol, high-density
lipoprotein cholesterol, triglycerides, and glucose were 1.0, 2.2, 1.5, and
1.4%. The mean CVs for ApoA-I, ApoB, hs-CRP, insulin, and C-peptide were
1.8, 2.0, 4.3, 2.4, and 2.5%, respectively.32
Analysis of polar metabolites
Serum polar metabolites were analyzed using comprehensive two-
dimensional gas chromatography combined with time-of-ﬂight mass
spectrometry (GC×GC–TOFMS, a LECO Pegasus 4D from Leco, St. Joseph,
MI, USA) with a method described in an earlier publication.34 In short,
protein precipitation by methanol was followed by two step derivatization
using methoximation and silylation. A set of internal standards (C17:0,
valine-d8, succinic acid-d4, n-alkane mixture and 4,4'-bibromooctaﬂuor-
obiphenyl) were added to the serum samples.
ChromaTOF vendor software (LECO) was used for within-sample data
processing, and Guineu software was used for alignment, normalization
and peak matching across samples.34 The normalization was performed by
correction for internal standards, and speciﬁc target metabolites were
additionally quantiﬁed using external calibration curves. Other mass
spectra from the GC×GC–TOFMS analysis were searched against the NIST
Mass Spectral Library and the Golm database, using also retention index
data in the identiﬁcation. Control serum samples were analyzed together
with the case samples.
All serum metabolite peaks that were present (had a non-zero value) in
more than 50% of the samples, including the unidentiﬁed ones, were
included in the data analyses. We reasoned that inclusion of complete data
as obtained from the platform best represent the global metabolome
covered by the platform. The unidentiﬁed peaks were annotated with their
structural class based on their mass spectra.34
Analysis of molecular lipids
Serum molecular lipids were analyzed using ultra performance liquid
chromatography coupled with time-of-ﬂight mass spectrometry (UPLC-
QTOFMS Q-Tof Premier mass spectrometer, Waters, Milford, MA, USA) with
a methodology described earlier.35 The samples were extracted with a
chloroform-methanol mixture after the addition of internal standards
containing LPC(17:0), PC(17:0/17:0), PE(17:0/17:0), Cer(d18:1/17:0) (Avanti
Polar Lipids, Alabaster, AL, USA), and TG(17:0/17:0/17:0) (Larodan Fine
Chemicals, Malmö, Sweden). External standard mixture containing (LPC
(16:0D3), PC(16:0/16:0D6) and TG(16:0/16:0/16:0-
13C3) (Larodan Fine
Chemicals, Malmö, Sweden) was added after the extraction. The data
processing using MZmine 2 [ref. 36] included the alignment of peaks, peak
integration, normalization, and peak identiﬁcation. Lipids were identiﬁed
using an internal spectral library or with tandem MS., The data were
normalized using lipid class-speciﬁc internal standards, as described in a
previous publication.35 Sphingomyelins were normalized with the PC
standard. Again, all lipidomic peaks, including the unidentiﬁed ones, were
included in the data analyses. Control serum samples and extracted
standard samples were analyzed together with the study samples.
Statistical analysis
Statistical analyses were done using the R statistical language37 (version
3.2.3). All statistical analyses of the lipidomic and metabolomic data were
based on log2-transformed intensity data. For improved global interpret-
ability and for the purpose of multivariate analysis, the transformed data
were centered and scaled based on the variable-speciﬁc mean and
standard deviation of the control samples.
The lipidomic and metabolomic variables were clustered using the
inﬁnite Gaussian mixture model38 with the variational Bayesian inference
algorithm39 implemented in the netresponse40 R package. The clusters
were inferred from the data of the control samples. The hyper-parameters
of the model were optimized based on the model ﬁt, which was quantiﬁed
by the lower bound of the data likelihood. For further analysis, the best-
ﬁtting model was selected from the 1000 candidate models that were ﬁt
with the optimized hyper-parameters, again based on the lower bound of
the data likelihood.
The inferred clusters were inspected for the enrichment of compound
groups with the binomial test for each cluster-compound group pair at a
false discovery rate (FDR)41 of 0.01. For the analysis of cluster levels, the
sample-speciﬁc median over the variables assigned to each cluster was
computed. Lipid clusters enriched with triacylglycerides were further
analyzed for the enrichment in the number of carbon atoms and in the
number of double bonds with the multinomial test at an FDR of 0.01.
Cluster-speciﬁc medians for the carbon number and the double-bond
count were also calculated.
Reported differences between the groups are median Glass’ Δ effects on
the log-transformed data. Case-control differences were computed
between the case group at the three time points (baseline, 2 months
and 1 year) and the control group.
Strength of the differences was assessed with a combination of the
Mann–Whitney U-test and the bootstrap test for non-zero effect. At each
test, 1000 bootstrap samples were drawn and the boundary of a strong
difference was set to Po0.05 simultaneously for both the tests. Non-
paired tests were used for the comparisons between groups of subjects
(case vs control, differences between the three treatment groups) and
paired tests were used for studying the temporal development of the case
subjects over the follow-up.
Metabolite levels at baseline were screened for associations to follow-up
changes in the clinical variables: Spearman correlation was computed
between cluster levels at baseline and absolute changes in clinical
variables between the baseline and the two follow-up time points.
Strength of the association was assessed with a combination of the
Spearman’s exact rank correlation test and the bootstrap test for Spearman
correlation coefﬁcient. At each test, 1000 bootstrap samples were drawn
and the boundary of a strong association was set to Po0.05
simultaneously for both the tests.
The levels of triacylglycerols (TGs) were analyzed for associations to
short-term follow-up relative changes in body mass. The association was
quantiﬁed by computing the Spearman correlation between the baseline
level of each compound and the change in the body mass between the
baseline and 2-month follow-up time points. These associations were
analyzed for the dependence on the two properties of the TG molecules:
the carbon number and the double-bond count. Two linear regression
models with each of the two feature variables as an independent variable
and the association to change in the body mass as a dependent variable
were ﬁt. The 95% conﬁdence intervals for the model ﬁt were computed
over 1000 bootstrap resamples.
RESULTS
Metabolic changes in ﬁrst-episode psychosis patients
The FEP patients (n= 36) were examined at baseline as well as at
the 2-month and 1-year follow-up time points, whereas the
control subjects (n= 19) were examined only at baseline
(Figure 1a). Although not different from the control group at
baseline (Table 1; Supplementary Text 1), the patients had
worsening metabolic characteristics over time, showing an
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increase in the body mass, waist circumference and serum insulin
during the follow-up (Table 1, Figure 1b). Two metabolomics
platforms with broad analytical coverage were applied to all
available samples from the FEP patients and controls: (a) global
lipidomics platform, based on ultrahigh performance liquid
chromatography coupled to mass spectrometry (UHPLC-QTOFMS),
covering molecular lipids including phospholipids, sphingolipids
and neutral lipids; (b) platform for global proﬁling of
polar metabolites, based on comprehensive two-dimensional
gas chromatography coupled to time-of-ﬂight mass spectrometry
(GC×GC–TOFMS), covering small molecules such as amino acids,
ketoacids, free fatty acids, various other organic acids, sterols and
sugars. The ﬁnal data set included 1148 molecular lipids and 363
polar metabolites from 19 controls and 36 FEP patients (36
subjects at baseline, 24 at 2 months and 12 at 12 months).
In order to reduce the dimensionality of the metabolomic data
and to increase its interpretability, we ﬁrst applied model-based
clustering. The clustering algorithm identiﬁed 25 lipidomic and 15
polar metabolite clusters (Table 2; LCs and MCs for lipid clusters
and metabolite clusters, respectively). Among the clusters, 14 lipid
clusters and 10 polar metabolite clusters were enriched with
respect to a speciﬁc structural group of metabolites. All seven TG-
enriched clusters were also enriched with respect to the carbon
number and the double-bond count (Table 2), indicating that the
TG clusters represent structurally distinct subgroups.
The levels of TGs were generally higher among the FEP patients
as compared to controls, both at baseline as well as throughout
the follow-up (Figure 1c). The between-group difference was most
consistent for a cluster containing polyunsaturated TGs (LC15 with
a median of eight unsaturated carbon–carbon bonds) at the
baseline and the increase remained strong at the 2-month follow-
up. Another TG cluster (LC17 with a median of three unsaturated
carbon–carbon bonds) had a consistent increase from the baseline
at the 1-year follow-up time point. In contrast, the case group had
lower levels of PCs with the most marked decrease at the 2-month
follow-up time point in LC12. Also, a metabolite cluster with three
unsaturated free fatty acids (MC15 with linolenic, eicosenoic and
pentadecanoic acids) was downregulated in cases as compared
with controls throughout the follow-up, with the most marked
difference already at the baseline time point.
Figure 1. (a) Schematic representation of the experimental design. (b) Relative weight gain (blue crosses) from baseline as a function of time
in the FEP case group. The median increase in body mass was 3 and 11 kg from baseline to the 2-month and 1-year follow-up points,
respectively. Nonlinear Gaussian process regression model was ﬁt on the weight gain data to visually highlight the trend. (c) Differences in the
medians between the case group in the three time points (columns) and control group for clinical variables, metabolite clusters (MCs) and
lipid clusters (LCs). Major differences between the case and control groups are highlighted with a diagonal cross (× ) and major differences
between the follow-up time points and the baseline time point among the case group are highlighted with a straight cross (+). Both the tests
are based on a coupled Mann–Whitney U-test and a bootstrap test of difference with simultaneously Po0.05 in both the tests used as a
threshold. Statistically signiﬁcant enrichment (at FDR 0.01) of a functional group in a cluster is shown in parenthesis following the cluster
name. FDR, false discovery rate; FEP, ﬁrst-episode psychosis.
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The effect of antipsychotic medication on metabolomic proﬁles
The median duration of antipsychotic medication was 27 days at
baseline (Supplementary Table 1). The strongest associations
between the duration of antipsychotic medication at baseline and
the metabolomic proﬁles at baseline were to the TG clusters LC6
and LC15 (Spearman r= 0.36 and 0.35, respectively, and both with
P= 0.04 in Spearman exact test but only LC15 with a non-zero 95%
Spearman r bootsrap conﬁdence interval; Supplementary Tables 2
and 3).
In the follow-up time points, the lipidomic levels were mainly
increased in patients administered olanzapine, when compared
with other treatments (Supplementary Figure 1). Particularly
increased were the two PC clusters (LC7 and LC12). Notably,
LC12 was also downregulated in patients at baseline. The
lipidomic levels were broadly decreased in patients administered
risperidone, when compared with other treatments
(Supplementary Figure 2). The decrease was strongest in three
bi- and monounsaturated TG clusters (LCs 8, 9 and 13).
Associations between metabolomic levels and clinical outcomes
Baseline levels of the PC cluster LC12 were associated to 2-month
changes in insulin resistance, serum C-peptide and waist-to-height
ratio and inversely associated to changes in the global assessment
of functioning (Figure 2). The association to the change in the
waist-to-height ratio remained strong in the subjects who were
lean at baseline (Spearman correlation r= 0.69; P= 0.02).
Two lipidomic clusters with an enrichment of PCs and
sphingomyelins (LC2 and LC3, respectively) were inversely
associated with a 2-month change in the BPRS (Figure 2). Levels
of clusters with mono- and bi-unsaturated TGs (LC9 and LC13), PCs
(LC7) and lysophosphatidylcholines (LPCs; LC11) were inversely
associated with follow-up changes in cholesterol and lipoproteins.
The clusters LC9, 13 and 11 were also inversely associated with the
2-month follow-up changes in insulin among subjects who were
lean at baseline (Spearman correlation r=− 0.59, P= 0.05; r=
− 0.68, P= 0.02; and r=− 0.67, P= 0.03, respectively).
As it is well known that only speciﬁc TGs, those with low carbon
number and double-bond count, associate with risk of type 2
diabetes, non-alcoholic fatty liver disease and insulin resistance,28–30
we set to examine how the TG composition associates with
metabolic outcomes in FEP patients. Indeed, the baseline levels of
TGs with a low double-bond count (including saturated and
monounsaturated TGs) and a low carbon number were all
positively associated with a 2-month change in the body mass
index (Figure 3).
DISCUSSION
Our ﬁndings based on comprehensive metabolomics analysis in a
prospective study setting demonstrate the potential of serum
metabolites to predict metabolic abnormalities in FEP patients.
Our study corroborates several earlier metabolomics ﬁndings
with respect to comparing psychotic patients and healthy controls
as well as to examinations of pharmacometabolomic proﬁles of
speciﬁc antipsychotic drugs. The strongest differences between the
FEP cases and controls, both at baseline and at the 2-month follow-
up, were observed for elevated polyunsaturated TGs and for the TG
(54:2). The latter has been proposed earlier as a biomarker of
schizophrenia.13 Increased levels of TGs in psychotic patients are
well-documented.42 The observed deﬁciency of essential fatty acids
has been previously attributed to drug-naive FEP.43
Abnormalities in sphingolipid metabolism have been previously
reported in the early stages of schizophrenia44,45 and are
suggestive of disrupted myelin.46 In the present study, the baseline
levels of sphingomyelin and PC clusters (LC3 and LC2, respectively)
were associated with the 2-month improvement in the Brief
Psychiatric Rating (BPRS). This indicates that aberrations in the
levels of sphingolipids, which are important for the structure and
function of cell membranes in the brain,47 might have potential for
predicting the severity of the psychotic condition.
Similar differential effect of olanzapine and risperidone on the
levels of PCs and TGs, as observed in the present study, has been
reported previously.12 Also, the levels of oleic and palmitic acids
have been reported to be altered by risperidone treatment,48
which is consistent with our observation that the metabolite
cluster MC11 was downregulated.
PCs have earlier been associated with insulin responsiveness.49
In this study, the baseline levels of a PC clusters were found
associated with 2-month increase in the insulin levels and waist-
to-height ratio. The phosphatidylcholine cluster LC12 had a group
effect, olanzapine effect as well as an association to follow-up
changes in insulin level and waist-to-height ratio and global
assessment of functioning, indicating a sensitivity to all three: the
Table 1. Baseline sociodemographic and clinical characteristics of the sample including FEP patients (n= 36) and controls (n= 19)
Control Case, baseline Case, 2 months Case, 1 year
Age 27 (23.7, 33.8) 24.5 (22, 29.5) 23.4 (21.7, 29.7) 26.7 (22.6, 33.4)
Brief Psychiatric Rating 24 (24, 25) 46 (39.5, 55) 36.5 (31.8, 43.2) 30.5 (25, 40.8)
Global assessment of functioning 90 (85, 90) 32 (30, 37.2) 38 (34.8, 40) 40 (37.2, 52.5)
Height 174 (168, 179) 175 (167, 183) 173 (166, 184) 172 (164, 181)
Male 10/19 (53%) 20/36 (56%) 11/24 (46%) 4/12 (33%)
Plasma glucose 4.2 (3.85, 4.42) 4.16 (3.84, 4.58) 4.2 (3.99, 4.41) 4.14 (4.06, 4.24)
Olazapine — 12/36 (33%) 5/24 (21%) 3/12 (25%)
Risperidone — 10/36 (28%) 5/24 (21%) 3/12 (25%)
Serum C-peptide 458 (367, 596) 553 (434, 868) 570 (433, 722) 544 (315, 720)
Serum HDL cholesterol 1.38 (1.34, 1.64) 1.37 (1.13, 1.54) 1.29 (1.15, 1.61) 1.22 (1.11, 1.67)
Serum LDL cholesterol 2.5 (2.11, 3.22) 2.86 (2.4, 3.5) 2.95 (2.43, 3.04) 2.64 (2.26, 3.3)
Serum insulin 7 (4.4, 9.35) 8.55 (6.15, 13.2) 8.35 (7.1, 14.2) 11.3 (8.15, 13.8)
Serum lipoprotein A-I 1.46 (1.37, 1.76) 1.42 (1.25, 1.52) 1.38 (1.23, 1.64) 1.37 (1.23, 1.68)
Serum lipoprotein B 0.69 (0.565, 0.86) 0.825 (0.66, 0.96) 0.815 (0.715, 0.935) 0.8 (0.61, 0.89)
Serum total cholesterol 4.58 (3.92, 5.6) 4.59 (4.21, 5.55) 4.79 (4.27, 5.34) 4.81 (4.15, 5.28)
Serum triglycerides 0.85 (0.71, 1.1) 1.1 (0.765, 1.37) 1.23 (0.792, 1.72) 0.98 (0.685, 1.94)
Waist 81 (76.5, 91) 83 (79, 89.2) 88.5 (82, 96.5) 91 (86.5, 97)
Weight 72.9 (63.1, 79.6) 69.7 (62, 79.1) 76 (60, 84.3) 74 (68, 95.8)
Abbreviations: FEP, ﬁrst-episode psychosis; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Data shown as n (%), or median (25%, 75% quartiles).
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psychosis, its treatment and the development of metabolic
syndrome.
LPCs have been considered as early biomarkers for the
development of type 2 diabetes.50 In this study, the baseline
levels of the LPC cluster (LC11) also were inversely associated with
the 2-month change in the insulin level among lean subjects,
indicating their potential as early predictors of metabolic
syndrome.
Our study also suggests that weight gain in FEP patients is
speciﬁcally associated with TGs with low carbon number and
double-bond count, and not with TGs in general. These speciﬁc
TGs are produced de novo in the liver28,51 and their circulating
levels also reﬂect the amount of liver fat.29 To our knowledge, this
ﬁnding is novel and potentially clinically important. It suggests
that patients with increased liver fat are at the highest risk of
gaining weight as the psychosis develops and when the
pharmacological treatment is initiated. These subjects are also at
the highest risk of developing metabolic co-morbidities associated
with psychosis and might therefore beneﬁt from an early anti-
obesity treatment together with the administration of antipsycho-
tics—a hypothesis that needs to be tested in the future.
Administration of metformin has already been suggested as an
option to counteract antipsychotic-induced weight gain.52
The main limitation of the present study is the relatively small
sample size, which did not allow us to develop diagnostic models
predictive of metabolic outcomes of psychotic patients. However,
the reported associations were also present in bootstrap-
resampled data, providing the evidence of robustness. Never-
theless, because of the limited sample size, the current results
should be seen as hypothesis generating and they need to be
replicated in a larger study sample.
As the time series structure of the data is limited to the case
group, it was not possible to fully untangle the temporal effects of
the psychotic condition and the antipsychotic medication from
the normal temporal variation over the follow-up. However, it is
known that in healthy subjects, the metabolite levels are stable
over time periods comparable to the follow-up time of this
study.53,54 The short period of antipsychotic treatment, already at
Figure 2. Associations between the baseline levels of the metabolite clusters (columns) and follow-up changes in the clinical variables (rows)
among case subjects are shown. Strongest associations (Po0.05 with both Spearman exact test and bootstrap test for Spearman correlation)
are highlighted with an asterisk. Lipidomic and metabolomic clusters (LCs and MCs, respectively) are annotated with light and dark gray colors
in the top margin and so are the 2-month and 1 year clinical change variables in the left margin. Statistically signiﬁcant enrichment (at FDR
0.01) of a functional group in a cluster is shown in parenthesis following the cluster name. FDR, false discovery rate.
Figure 3. Association between the level of triacylglycerols (TGs) at
baseline and the 2-month follow-up weight gain (Spearman
correlation; color of the points) with respect to the number of
carbon atoms (x-axis) and the number of double bonds between
carbon atoms (y axis). The baseline levels of saturated and
monounsaturated compounds (y= 0 and y= 1, respectively) are
associated with short-term weight gain (red color). The coefﬁcient of
determination (R2) of the linear model for the association as a
function of triacylglycerol carbon number and double-bond count
are shown in the x axis and y axis labels, respectively (both Po0.05).
Metabolome in co-morbidities of psychosis
T Suvitaival et al
7
Translational Psychiatry (2016), 1 – 9
the baseline sampling point for most subjects, sets another
limitation to the full statistical separation of the effects of
psychotic condition from the effects of antipsychotic medication.
Further improvement in this part of the study design is hard to
achieve due to the severity of psychotic condition but could result
in a more precise characterization of aberrations that are directly
related to psychosis. On the other hand, other studies have
focused on short time periods similar to the ﬁrst follow-up time
point of the present study, whereas the last follow-up time point
here is relatively far ahead, presenting new data on the medium-
term effects. Even longer follow-up durations than in the present
study could be useful for conﬁrming the disease outcomes such as
the eventual diagnosis of type 2 diabetes.
Taken together, the detected associations indicate that
metabolite proﬁles may be used to identify those psychotic
patients, who are the most vulnerable to developing metabolic co-
morbidities. Future studies with larger sample sizes over longer
periods of follow-up are needed for deriving and validating
diagnostic models for the identiﬁcation of subjects at highest risk
of metabolic co-morbidities and for the prediction of their
metabolic outcomes. Further, designed intervention studies are
needed for assessing the preventive effects of an early anti-
obesity treatment in this metabolic high-risk subgroup of FEP
patients.
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